Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study

The aim of this study was to evaluate feasibility and toxicity of escalating doses of epirubicin and paclitaxel plus fixed dose of etoposide and to define the activity of the triplet in extensive disease small-cell lung cancer. Thirteen patients entered the phase I study: the maximum tolerated doses...

Descripción completa

Detalles Bibliográficos
Autores principales: Tibaldi, C, Prochilo, T, Russo, F, Pennucci, M C, Del Freo, A, Innocenti, F, Fabbri, A, Falcone, A, Conte, P F, Baldini, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361402/
https://www.ncbi.nlm.nih.gov/pubmed/16622468
http://dx.doi.org/10.1038/sj.bjc.6603074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361402/
https://www.ncbi.nlm.nih.gov/pubmed/16622468
http://dx.doi.org/10.1038/sj.bjc.6603074

Ejemplares similares